drugset / Trial / NCT00814944

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

NCT00814944

Phase 2 Completed 143 enrolled Santen Inc. MacuSight, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation compared to Placebo on the signs and symptoms of dry eye in the CAE Model.

Timeline

Start
2009-04
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sirolimus Small molecule 220 ug Other
Comparator Sirolimus Small molecule 440 ug Other
Comparator Sirolimus Small molecule 880 ug Other

Indications